Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AVTR 
Avantor Inc (AVTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: AVTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $10.89
1 Year Target Price $10.89
| 6 | Strong Buy |
| 4 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.28B USD | Price to earnings Ratio - | 1Y Target Price 10.89 |
Price to earnings Ratio - | 1Y Target Price 10.89 | ||
Volume (30-day avg) 21 | Beta 0.95 | 52 Weeks Range 8.89 - 18.02 | Updated Date 02/20/2026 |
52 Weeks Range 8.89 - 18.02 | Updated Date 02/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-11 | When - | Estimate 0.2168 | Actual 0.22 |
Profitability
Profit Margin -8.09% | Operating Margin (TTM) 10.17% |
Management Effectiveness
Return on Assets (TTM) 2.96% | Return on Equity (TTM) -9.2% |
Valuation
Trailing PE - | Forward PE 13.93 | Enterprise Value 9903558489 | Price to Sales(TTM) 0.96 |
Enterprise Value 9903558489 | Price to Sales(TTM) 0.96 | ||
Enterprise Value to Revenue 1.51 | Enterprise Value to EBITDA 71.4 | Shares Outstanding 682055932 | Shares Floating 664172425 |
Shares Outstanding 682055932 | Shares Floating 664172425 | ||
Percent Insiders 1.4 | Percent Institutions 103.64 |
Upturn AI SWOT
Avantor Inc
Company Overview
History and Background
Avantor Inc. was founded in 1904 as J.T. Baker Chemical Company. It evolved through various ownerships, including Mallinckrodt and Ceridian, before being acquired by New Mountain Capital in 2010 and rebranded as Avantor. It went public in 2019. Avantor is a global provider of mission-critical products and services to customers in the life sciences, advanced technologies, and applied materials industries.
Core Business Areas
- Life Sciences: Serves biopharmaceutical, healthcare, and medical device industries with a broad portfolio of lab consumables, equipment, chemicals, and reagents for research, development, and production. This includes bioprocessing solutions for drug manufacturing.
- Advanced Technologies and Applied Materials: Provides high-purity chemicals, materials, and services to customers in industries such as semiconductors, aerospace, and electronics, enabling innovation and manufacturing processes.
Leadership and Structure
Avantor is led by a CEO and a senior executive team. The company is organized into various functional departments and operational units that support its global business segments and customer needs.
Top Products and Market Share
Key Offerings
- Product Name 1: Bioprocessing Solutions (e.g., single-use technologies, cell culture media, chromatography resins). Market share data is proprietary and not publicly disclosed, but this is a significant growth area. Competitors include Thermo Fisher Scientific, Sartorius, Danaher (Cytiva).
- Product Name 2: Lab Consumables and Equipment (e.g., glassware, pipettes, filtration products, centrifuges). Competitors include Thermo Fisher Scientific, VWR (now part of Avantor), Fisher Scientific.
- Product Name 3: High-Purity Chemicals and Reagents (e.g., solvents, acids, analytical standards). Competitors include Merck KGaA (MilliporeSigma), Thermo Fisher Scientific, Honeywell.
Market Dynamics
Industry Overview
Avantor operates within the global life sciences, diagnostics, and advanced materials markets, which are characterized by strong growth driven by increasing healthcare spending, R&D investment in biopharmaceuticals, and technological advancements in various industries. The demand for high-quality, reliable products and services is paramount.
Positioning
Avantor is positioned as a leading global provider of mission-critical products and services with a broad portfolio and a strong distribution network. Its competitive advantages include its comprehensive product offering, global reach, established customer relationships, and focus on innovation and quality.
Total Addressable Market (TAM)
The TAM for Avantor's served markets is in the hundreds of billions of dollars, encompassing laboratory supplies, bioprocessing, chemicals, and reagents. Avantor addresses a significant portion of this TAM through its diverse product and service offerings and global presence.
Upturn SWOT Analysis
Strengths
- Broad and integrated product and service portfolio.
- Strong global distribution network and customer relationships.
- Leadership position in key segments like bioprocessing.
- Focus on innovation and high-quality products.
- Acquisition strategy to expand capabilities.
Weaknesses
- Integration challenges from past acquisitions.
- Dependence on key suppliers for certain raw materials.
- Potential for supply chain disruptions.
- Competitive pricing pressures in some segments.
Opportunities
- Growing demand for biopharmaceuticals and biologics.
- Expansion in emerging markets.
- Increased outsourcing of lab services by biopharma companies.
- Technological advancements requiring specialized materials.
- Further consolidation within the industry.
Threats
- Intense competition from established players and new entrants.
- Economic downturns impacting R&D spending.
- Regulatory changes affecting the life sciences industry.
- Geopolitical risks and supply chain disruptions.
- Rapid technological obsolescence.
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Merck KGaA (MRK, listed on XTRA)
- Sartorius AG (SRT3, listed on XTRA)
Competitive Landscape
Avantor holds a strong position due to its comprehensive offering and global reach. However, it faces intense competition from larger, diversified players like Thermo Fisher Scientific and Danaher. Avantor's advantage lies in its specialized focus on mission-critical products and services, particularly in the biopharma sector.
Major Acquisitions
VWR International
- Year: 2017
- Acquisition Price (USD millions): 6500000
- Strategic Rationale: Acquired VWR, a major global laboratory product and service provider, significantly expanding Avantor's scale, product breadth, and geographic reach, particularly in the life sciences and research markets.
Cytiva's research and development consumables business from Danaher
- Year: 2022
- Acquisition Price (USD millions): 760
- Strategic Rationale: Strengthened Avantor's bioprocessing portfolio, particularly in single-use technologies and cell and gene therapy consumables, enhancing its position in a high-growth segment of the life sciences market.
Growth Trajectory and Initiatives
Historical Growth: Avantor has experienced significant historical growth, fueled by both organic expansion and a series of strategic acquisitions that have broadened its product portfolio and market reach. The company has consistently focused on increasing its market share in key life science and advanced technology sectors.
Future Projections: Analyst projections for Avantor's future growth are generally positive, anticipating continued expansion driven by the strong underlying trends in the life sciences and advanced materials industries. Key growth drivers include the biopharmaceutical sector, demand for innovative diagnostic tools, and the semiconductor industry.
Recent Initiatives: Recent initiatives have included ongoing integration of acquisitions, expansion of bioprocessing capabilities, development of new product lines, and investments in digital transformation to enhance customer experience and operational efficiency.
Summary
Avantor Inc. is a strong player in the global life sciences and advanced materials markets, benefiting from robust industry tailwinds. Its comprehensive product portfolio and extensive distribution network are key strengths. While facing intense competition and potential integration challenges, the company is well-positioned to capitalize on the growing demand for biopharmaceuticals and innovative materials. Continued focus on strategic acquisitions and organic growth initiatives will be crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Avantor Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Financial news outlets (e.g., Wall Street Journal, Reuters)
- Industry analysis reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market share estimates are subject to change and may vary depending on the source. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avantor Inc
Exchange NYSE | Headquaters Radnor, PA, United States | ||
IPO Launch date 2019-05-17 | President, CEO & Director Mr. Emmanuel Ligner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.avantorsciences.com |
Full time employees 13500 | Website https://www.avantorsciences.com | ||
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.